WuXi Biologics
RU-friendlyGlobal CDMO powerhouse — open-access biologics platform covering cell line development through Phase 1–3 and commercial manufacturing for 800+ integrated projects.
- Country
- China
- Revenue
- RMB 18.7B
- Employees
- ~14,000 emp
FDA GMP
GMP EU
NMPA GMP
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| market-access-commercial | ✓ | ✓ | ✓ | ✓ |
| therapeutics-platforms | ✓ | ✓ | — | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biologics | therapeutics-platforms | Low | → |
| Bioproduction CDMO/CMO (biologics/ATMP/mRNA) | therapeutics-platforms | Low | → |
| Local manufacturing for market access | market-access-commercial | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.